<< Back
Cristina Csimma, Pharm. D., M.H.P.

Cristina Csimma, Pharm. D., M.H.P. was appointed a member of Idera’s Board of Directors in April, 2019. Dr. Csimma currently serves as an independent Director of Neuralstem. Inc. and is a Board Director of T1D Exchange (non-profit-Type 1 Diabetes). She also serves on advisory boards including the Muscular Dystrophy Association Venture Philanthropy Scientific Advisory Committee; the Executive Oversight Board to the National Institutes of Health (NIH) NeuroNext Network, the Harvard and Brigham and Women’s Hospital MRCT Center External Advisory Board, and the TREAT-NMD Advisory Committee for Therapeutics (TACT). Dr. Csimma previously served as a director on the boards of Juniper Pharma, Vtesse Pharma, was the Executive Chair of Exonics Therapeutics, and was President, founding CEO and Board Director of Cydan Inc. She also served on the NIH Blueprint Neurotherapeutics Network External Oversight Committee, was Vice President of Drug Development at Virdante Pharmaceuticals Inc., Principal at Clarus Ventures LLC and held roles of increasing responsibility in Clinical Development and Translational Research at Wyeth, Genetics Institute and Dana Farber Cancer Institute. 

Dr. Csimma holds both a Doctor of Pharmacy and a Bachelor of Science in Pharmacy from the Massachusetts College of Pharmacy and Allied Health Sciences, as well as a Master of Health Professions from Northeastern University.